Angina Drug Shows Promise for Type of Pulmonary Hypertension
(MedPage Today) The anti-angina agent ranolazine (Ranexa) may work in a condition for which there are few options in terms of drug therapy: pulmonary hypertension (PH) tied to heart failure with preserved ejection fraction (HF-pEF), researchers found. Read article
Friday, November 01, 2013 4:48:00 PM
Pulmonary Hypertension Spotlighted at CHEST
Five staff members represented the Pulmonary Hypertension Association at this year’s meeting of the American College of Chest Physicians.
- Rino Aldrighetti, President & CEO
- Carl Hicks, Executive Vice President
- Lisa Beth Gansberg, Executive Director, Midwest Chapter
- Michael Patrick Gray, Director, Medical Services
- Briana Rivas-Morello, Patient Education Associate
Many physicians with whom PHA works closely gave talks on various diagnostic and management issues related to PH to a particularly receptive audience, given the increased PH presence at this year’s meeting. Read this MedPage Today article on how pulmonary hypertension was in the spotlight at CHEST
Thursday, October 31, 2013 4:50:00 PM
New Criteria Could Lead to Earlier Diagnosis of Scleroderma
(National Pain Report) A new classification criterion for systemic sclerosis, a chronic autoimmune disease also known as scleroderma, could help physicians diagnose and begin treating patients sooner. The new criteria, developed by a joint committee formed by the American College of Rheumatology (ACR) and the European League Against Rheumatism, are published in the ACR journal, Arthritis & Rheumatism. They are the first changes in the criteria since 1980. Read article
Saturday, October 19, 2013 4:14:00 PM
Eleventh PH Drug Approved, The Second in Just Ten Days
Today the U.S. Food and Drug Administration (FDA) approved the eleventh pulmonary arterial hypertension (PAH) treatment in the U.S., Actelion Pharmaceutical’s macitentan (commercially known as Opsumit), an oral dual endothelin-receptor antagonist. This comes just ten days after the approval of riociguat (commercially known as Adempas) for the treatment of PAH and some cases of chronic thromboembolic pulmonary hypertension (CTEPH). These two new drugs are the first in five years to be approved by FDA for treating PH.
According to Healio, the phase 3 SERAPHIN drug trial for macitentan was the first to test a PAH drug for its effects on morbidity and mortality. Patients who took the drug showed lower rates of morbidity and mortality as compared to patients who received a placebo, showed improved six-minute walk tests and more showed improvement in their WHO functional class.
Acknowledging the achievement of adding an eleventh drug to the choices for PAH patients in a rare disease state, PHA President Rino Aldrighetti said, “Of the 7,000 rare diseases, only three have as many or more treatments available. We are fortunate to have a strong and growing research community with great communication and cooperation. That has helped foster industry interest in exploring new options for patients.”
PHA itself has committed more than $12.5 million to support cutting-edge research focused on pulmonary hypertension. PHA has been able to leverage such substantial funding through partnerships with the National Heart, Lung, and Blood Institute (NHLBI), American Thoracic Society (ATS), American Heart Association (AHA), and Pfizer.
We know that your ultimate wish is for a cure, and that is why PHA will continue to support the work of researchers until the day when no one suffers from PH.
Learn more: FDA press release | macitentan study findings | PH treatments in the U.S. | PH treatments worldwide | PHA Research Program
Friday, October 18, 2013 4:11:00 PM
Researchers Identify Possible Treatment Avenues for Scleroderma
(Science Codex) Using mice, lab-grown cells and clues from a related disorder, Johns Hopkins researchers have greatly increased understanding of the causes of , showing that a critical culprit is a defect in the way certain cells communicate with their structural scaffolding. They say the new insights point the way toward potentially developing drugs for the disease, which affects approximately 100,000 people in the United States. Read article
Friday, October 18, 2013 4:03:00 PM